Athira Pharma (NASDAQ:ATHA) Stock Price Up 0.6% – Still a Buy?

Athira Pharma, Inc. (NASDAQ:ATHA) was up 0.6% during mid-day trading on Monday . The stock traded as high as $5.06 and last traded at $4.74. Approximately 50,082 shares changed hands during trading, a decline of 98% from the average daily volume of 3,210,973 shares. The stock had previously closed at $4.71.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Athira Pharma in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell” and an average target price of $4.00.

Athira Pharma Trading Up 0.6%

The stock has a market capitalization of $18.69 million, a P/E ratio of -0.49 and a beta of 2.79. The business has a fifty day simple moving average of $5.74 and a 200 day simple moving average of $4.65.

Athira Pharma (NASDAQ:ATHA) last posted its earnings results on Thursday, November 6th. The company reported ($1.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($1.51). As a group, research analysts forecast that Athira Pharma, Inc. will post -2.35 earnings per share for the current year.

Hedge Funds Weigh In On Athira Pharma

A hedge fund recently raised its position in Athira Pharma stock. BML Capital Management LLC increased its holdings in shares of Athira Pharma, Inc. (NASDAQ:ATHA) by 0.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,230,667 shares of the company’s stock after acquiring an additional 30,000 shares during the quarter. Athira Pharma makes up about 0.7% of BML Capital Management LLC’s holdings, making the stock its 17th largest position. BML Capital Management LLC owned about 8.27% of Athira Pharma worth $976,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 57.12% of the company’s stock.

About Athira Pharma

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.